
Credit: Isomorphic Labs
Six months after raising $2.1 billion, Alphabet-controlled Isomorphic Labs has secured another $5 billion to expand its AI drug-design engine and advance its first therapeutic programs toward human trials. Greenoaks and Sequoia Capital co-led the Series C round, announced Nov. 17, for the company led by Nobel laureate Demis Hassabis.
BioSpace calls the financing the largest venture round in biotech history, surpassing the $3 billion Altos Labs raised at its 2022 launch. It also more than doubles Isomorphic’s $2.1 billion Series B from May. For comparison, fellow AI drug developer Xaira Therapeutics launched in April 2024 with more than $1 billion in committed capital. BioSpace counts at least $7.7 billion raised by Isomorphic since March 2025.
Andreessen Horowitz and several other new investors joined the round. Alphabet invested again, and every existing backer took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Alphabet holds 75% or more of Isomorphic’s shares and voting rights, according to UK Companies House records that reflect a June share allotment. Hassabis, Isomorphic’s CEO since its 2021 spinout from DeepMind, stepped down as Google DeepMind’s CEO in August to become its chairman and Alphabet’s chief scientist. Bloomberg had reported Nov. 4 that the company was in talks to raise about $5 billion at a valuation of roughly $50 billion.
Isomorphic says it will spend the money maturing IsoDDE, its proprietary drug design engine, which it describes as a suite of simulation models that work across therapeutic areas and drug modalities. The company also plans to build what it calls global infrastructure for AI-led bioengineering, along with translational and clinical development infrastructure for moving candidates into trials. “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients,” Hassabis said in the release.
Isomorphic keeps its newest models closer than DeepMind kept the first three AlphaFold generations. The two companies developed AlphaFold 3 together and published it in May 2024 with access through the web-based AlphaFold Server, then released its code and, under non-commercial terms, its model weights that November. Isomorphic described IsoDDE on Feb. 10 in a technical report without code, weights or training details, and the company has no plans to reveal the “secret sauce,” Nature reported. Isomorphic puts its models to work through its internal drug programs and partnerships with companies like Eli Lilly, Novartis and Johnson & Johnson. “We’re not selling access to the models, we’re not selling tokens or API access,” President Max Jaderberg said at Bloomberg Tech in London on Nov. 2.
The round adds to a fast-rising flow of money into AI drug discovery. Investor funding for AI-enabled drug discovery more than doubled from $4.1 billion in 2023 to $8.4 billion in 2025, and headline AI deal value among the top 20 drugmakers doubled to $29.5 billion in 2025, McKinsey reported in September, as R&D World covered. Drugmakers paid 2% of that 2025 deal value up front and tied 60% to 90% to later clinical and commercial milestones. Drug discovery startups have raised a record $23.2 billion so far in 2026, according to Dealroom figures cited by CNBC.
Isomorphic’s milestones remain preclinical. The company says its models are producing positive preclinical results in internal oncology and immunology programs and with partners, “setting the stage for clinical entry.” At the same London event, Jaderberg described the programs as “deep in pre-clinical development,” R&D World reported. Hassabis said at Davos in January that Isomorphic expected its first clinical trials by the end of 2026, Reuters reported. That target replaced his earlier goal of AI-designed drugs in trials by the end of 2025, and it is now six weeks away.




Tell Us What You Think!
You must be logged in to post a comment.